Evidence map›Paper›PMID 42443469›Full record

ArticleBone marrow transplantation2026

Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Arnon Nagler, Jordi Esteve, Jacques-Emmanuel Galimard, Depei Wu, Erlie Jiang, Nathalie Dhedin, Anne Sirvent, Jan Vydra, Jakob Passweg, Bruno Lioure and 13 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Arnon Nagler *Division of Hematology, Sheba Medical Center, Tel Hashomer, and Tel Aviv University, Tel Aviv, Israel. arnon.nagler@sheba.health.gov.il.ORCID http://orcid.org/0000-0002-0763-1265
Jordi Esteve *Hematology Department, Institute of Cancer & Blood Disorders (ICAMS), Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8056-648X
Jacques-Emmanuel GalimardEBMT Paris Study Unit, Paris, France.
Depei WuFirst-Affiliated Hospital of Soochow University, Suzhou, China.ORCID http://orcid.org/0000-0002-6312-3863
Erlie JiangInstitute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China.ORCID http://orcid.org/0000-0003-0237-6063
Nathalie DhedinHematology Unit for Adolescents and Adults, Saint Louis Hospital, Paris, France.ORCID http://orcid.org/0009-0003-3085-6539
Anne SirventCHU Lapeyronie, Montpellier, France.
Jan VydraInstitute of Hematology and Blood Transfusion, Prague, Czechia.ORCID http://orcid.org/0000-0002-4274-3895
Jakob PasswegUniversity Hospital Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0001-7092-3351
Bruno LioureICANS - Institut de cancerologie Strasbourg Europe, Strasbourg, France.
Jaime SanzHematology Department, Hospital Universitari i Politècnic La Fe, Valencia Departament de Medicina Universitat de Valencia, CIBERONC, Instituto Carlos III, Madrid, Spain.ORCID http://orcid.org/0000-0001-6934-4619
Jurjen VersluisErasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0003-2372-1663
Yajing XuCentral South University - Xiangya Hospital, Changsha, China.
Cristina Castilla-LlorenteGustave Roussy Cancer Campus, Villejuif, France.ORCID http://orcid.org/0000-0002-7728-5804
Rodrigo Martino BufarullHospital Santa Creu i Sant Pau, Barcelona, Spain.ORCID http://orcid.org/0000-0001-5143-4042
Victoria PotterKings College Hospital, London, United Kingdom.
Nour Ben AbdeljelilCentre National de Greffe de Moelle, Tunis, Tunisia.
Eolia BrissotService d'Hématologie clinique et thérapie cellulaire, Hôpital Saint-Antoine, APHP, Paris, France.ORCID http://orcid.org/0000-0003-4471-418X
Ali BazarbachiHematology-Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.ORCID http://orcid.org/0000-0002-7171-4997
Bipin SavaniVanderbilt University Medical Center, Nashville, TN, USA.
Sebastian GiebelMaria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.ORCID http://orcid.org/0000-0002-4827-4401
Mohamad MohtySorbonne University, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Paris, France.ORCID http://orcid.org/0000-0002-7264-808X
Fabio CiceriOspedale San Raffaele, Haematology and BMT, Milano, Italy.ORCID http://orcid.org/0000-0003-0873-0123

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We compared the presence of additional chromosomal abnormalities (ACAs, n = 345) with a referent group with no ACAs (n = 169) (noACAs) in patients with Ph+ ALL receiving TKI before transplantation. The groups did not differ significantly in age, gender, or interval from diagnosis to transplantation. More patients with ACAs received PB grafts (86.4% vs. 78.1%, p = 0.03), while more patients in the noACAs group received myeloablative conditioning (87% vs. 75.9%, p = 0.003). Day 30 ANC (≥10

Indexed as

Chromosome AberrationsHematopoietic Stem Cell TransplantationPhiladelphia ChromosomePrecursor Cell Lymphoblastic Leukemia-LymphomaTransplantation ConditioningAdolescentAdultChildFemaleGraft vs Host DiseaseHumansMaleMiddle AgedTreatment OutcomeYoung Adult

Identifiers

PMID42443469
PMCPMC13569436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.